Skip to main content

Table 1 Patient demographics

From: The “real life” efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP

 

Initial TPS ≤ 4

Initial TPS ≥ 5

Total

Total [%]

61 [62.9%]

36 [37.1%]

97 [100%]

Male [%]

34 [55.7%]

27 [75%]

61 [62.9%]

Female [%]

27 [44.3%]

9 [25%]

36 [37.1%]

Age [SD]

45.7 [14.5]

47.3 [13.8]

46.3 [14.2]

YoD [IQR]

2010 [2000–2014]

2005 [1999–2013]

2010 [2000–2013]

Asthma [%]

45 [73.8%]

18 [50%]

63 [64.9%]

Allergy [%]

44 [72.1%]

24 [66.7%]

68 [70.1%]

N-ERD [%]

34 [55.7%]

16 [44.4%]

50 [51.5%]

No. ESS [IQR]

2 [1–3]

2 [1–2]

2 [1–3]

  1. YoD year of diagnosis, SD standard deviation, IQR interquartile range, N-ERD NSAID-exacerbated respiratory disease, ESS endoscopic sinus surgery, TPS total polyp score